Jasper Therapeutics Reports Q1 Results, Needs Additional Funding to Start Key Phase 2b Study
JSPR sits 54% above its 52-week low of $0.623.
Summary
Jasper Therapeutics reported its first quarter 2026 financial results, showing $14.1 million in cash and cash equivalents as of March 31, 2026, and a net loss of $1.2 million. The company provided a corporate update, reiterating positive updated clinical data for briquilimab in chronic spontaneous urticaria (CSU) from earlier studies and confirming the refiling of its Phase 2b protocol with the FDA. Critically, Jasper stated it is working to secure additional funding to enable the commencement of this planned Phase 2b study in the second half of 2026. This dependency on new financing for a pivotal clinical trial is a material concern for a clinical-stage biotechnology company, despite the positive data. Investors will be closely monitoring the company's progress in securing the necessary funding to advance its lead therapeutic candidate.
At the time of this announcement, JSPR was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.8M. The 52-week trading range was $0.62 to $7.19. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.